AUTHORS
Michael Malloy, James Palis, MD2, Craig Morrell, DVM, PhD3
AFFILIATIONS
1 University of Rochester, Rochester, New York, United States
2 University of Rochester, Rochester, New York, United States
3 University of Rochester, Rochester, New York, United States
ABSTRACT
Platelets are dynamic cells that perform vital roles in both thrombosis and immune regulation. Platelet functions extend beyond the platelet activation phase following a vascular lesion through their expression and secretion of angiogenic factors and immune mediators that initiate wound healing and recruit leukocytes to prevent infection. Many studies have shown that platelets are heterogenous, as RNA-seq and proteomics have both shown differences in platelet phenotypes and functions in multiple disease conditions. Megakaryocytes (Mks) are the platelet progenitor and are present and produce platelets in the bone marrow (BM), lungs and spleen. Although thrombopoiesis represents the canonical Mk role, Mk phenotype and function vary considerably. Mks within the BM have described heterogeneity that may contribute to platelet heterogeneity, as platelets are both the cellular mediators of thrombosis and immune regulatory cells. Single-cell RNA sequencing (scRNA-seq) has suggested distinct BM Mk subtypes based on their genetic makeup that may facilitate more specialized roles in platelet generation, immune responses (lower ploidy), Mk cycling/growth (higher ploidy), and hematopoietic stem cell (HSC) niche support. Lung Mks are low ploidy and immune differentiated, reflective of the low ploidy BM immune Mk phenotype. To identify potential mediators of Mk immune differentiation we used single cell and bulk RNA-seq data comparing BM and lung Mks and identified the transcription factor Myb as being highly expressed in BM, but not lung Mks. Myb is a proto-oncogene transcription factor that has an essential role in the regulation of hematopoiesis and mutations in Myb result in leukemias and lymphomas. We therefore tested whether Myb expression limits Mk immune differentiation.
Using a Myb-GFP reporter mouse that marks all cells actively expressing Myb, we found that approximately 80% of BM Mks express Myb (Myb-GFP+ve), while ~95% of lung Mks lack Myb expression (Myb-GFP-ve). Notably, 20% of BM Mks lack Myb expression and exhibit an immune phenotype typified by increased surface expression of Mk immune-associated molecules such as MHC-II and ICAM1. To determine regulator of Mk Myb expression, we challenged mice with inflammatory stimuli, including interferons and Toll-like receptor (TLR) agonists and found that Mk Myb expression is dynamic and the proportion of Myb-ve BM Mks greatly increased following immune challenge. Following inflammatory stimulation, the Myb-ve Mks exhibited elevated expression of ICAM1, MHC-I, MHC-II, and CCR7 compared to Myb+ve Mks. We next sought to determine the role of Myb in Mks during disease associated immune responses by challenging mice with the non-lethal malaria strain Plasmodium yoelii (PyNL). Following infection, there was an increase in the proportion of Myb-ve BM Mks, accompanied by increased expression of Mk immune-associated molecules.
To explore the functional role of Myb in Mks, we crossed PF4cre and Mybfl/fl mice to make PF4-Myb-/- mice which had a distinct immune differentiated phenotype characterized by reduced ploidy, increased expression of TLRs, and the generation of immune-skewed platelets compared to WT mice. RNA-seq on flow-sorted WT and PF4-Myb-/- Mks revealed increased expression of proteasomal, inflammatory, and apoptosis regulator pathway associated genes in PF4-Myb-/- Mks. Platelets derived from PF4-Myb-/- had increased responses to TLR agonists and formed increased numbers of platelet-leukocyte aggregates (PLAs) in vivo.
Collectively, these data demonstrate BM Mk immune plasticity that is at least in part dynamically regulated by Myb expression that limits immune differentiation and that inflammation reduced Mk Myb leading to the production of immune-skewed Mks and platelets. Furthermore, we demonstrated that the immune phenotype of Mks is dynamically modified in response to systemic inflammatory challenge and infection.
DISCLOSURES
Michael Malloy: No relevant conflicts of interest to declare.